Bupropion SR and counseling for smoking cessation in actual practice: predictors of outcome.
Bupropion SR and counseling for smoking cessation in actual practice: predictors of outcome.
复制标题
安非他酮 SR 和实际戒烟咨询：结果的预测因素。
DOI：
10.1080/14622200310001646903
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
Dacey,Sara
中科院分区：
文献类型：
--
作者：
Swan,GaryE;Jack,LisaM;Curry,Sue;Chorost,Michael;Javitz,Harold;McAfee,Tim;Dacey,Sara
迄今为止，只有一项研究发表了与安非他酮SR戒烟标准治疗结果相关的个体特征。为了调查超过6周治疗终点的治疗结果，本研究在一个大型卫生保健系统中研究了安非他酮SR治疗后与临床相关的吸烟终点相关的特征。共有1524名平均年龄为45.1岁的吸烟者（649名男性和875名女性）随机接受安非他酮SR（150或300毫克）和行为咨询（量身定制的邮件或主动电话咨询）的四种组合之一，并在3个月和12个月时评估点流行吸烟状况。对治疗后12个月点流行吸烟和持续吸烟（两次随访均为点流行吸烟）的潜在危险因素进行多重logistic回归分析。在合并样本的两个终点，吸烟的危险因素包括：定制邮寄治疗、女性性别、年轻、较高程度的烟草依赖、较短的戒烟尝试、以前使用尼古丁替代疗法、目前有抑郁症状或终生抑郁的报告。女性治疗后吸烟的危险因素仅包括低剂量安非他酮SR治疗、年轻和高感知压力，而男性独有的危险因素包括终生抑郁的存在。研究结果表明，总体上需要更有效的治疗方法，个体差异在戒烟治疗后重新吸烟的可能性中所起的作用。
To date, only one study has been published on individual characteristics associated with outcome following standard treatment with bupropion SR for smoking cessation. To investigate treatment outcome beyond the 6-week end-of-treatment point, the present study examined characteristics associated with more clinically relevant smoking endpoints following treatment with bupropion SR in a large health care system. A total of 1,524 smokers (649 men and 875 women) of average age 45.1 years were randomized to receive one of four combinations of bupropion SR (150 or 300 mg) and behavioral counseling (tailored mailings or proactive telephone counseling) and assessed for point-prevalent smoking status at 3 and 12 months. Multiple logistic regression analyses of potential risk factors for 12-month point-prevalent smoking and for persistent smoking (point-prevalent smoking at both follow-ups) following treatment were conducted for men and women combined and separately. Risk factors for smoking at both endpoints in the combined sample included treatment with tailored mailings, female gender, younger age, higher levels of tobacco dependence, shorter previous quit attempts, previous use of nicotine replacement therapy, and report of current depressive symptoms or lifetime depression. Risk factors for smoking following treatment identified in women only included treatment with the lower dose of bupropion SR, younger age, and higher perceived stress, whereas those that were unique to men included the presence of lifetime depression. The results are discussed in terms of their implications for the need for more effective treatments in general, and the role of individual differences in the likelihood of returning to smoking following treatment for quitting.